AllylestrenolCAS# 432-60-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 432-60-0 | SDF | Download SDF |
| PubChem ID | 235905 | Appearance | Powder |
| Formula | C21H32O | M.Wt | 300.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (166.40 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (8R,9S,10R,13S,14S,17R)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol | ||
| SMILES | CC12CCC3C(C1CCC2(CC=C)O)CCC4=CCCCC34 | ||
| Standard InChIKey | ATXHVCQZZJYMCF-XUDSTZEESA-N | ||
| Standard InChI | InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Allylestrenol Dilution Calculator
Allylestrenol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.3278 mL | 16.6389 mL | 33.2779 mL | 66.5557 mL | 83.1947 mL |
| 5 mM | 0.6656 mL | 3.3278 mL | 6.6556 mL | 13.3111 mL | 16.6389 mL |
| 10 mM | 0.3328 mL | 1.6639 mL | 3.3278 mL | 6.6556 mL | 8.3195 mL |
| 50 mM | 0.0666 mL | 0.3328 mL | 0.6656 mL | 1.3311 mL | 1.6639 mL |
| 100 mM | 0.0333 mL | 0.1664 mL | 0.3328 mL | 0.6656 mL | 0.8319 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SJ 172550
Catalog No.:BCC2416
CAS No.:431979-47-4
- 7'-O-Ethylmarmin
Catalog No.:BCC8274
CAS No.:
- Necrostatin-1
Catalog No.:BCC2247
CAS No.:4311-88-0
- DPO-1
Catalog No.:BCC7398
CAS No.:43077-30-1
- Umckalin
Catalog No.:BCC9211
CAS No.:43053-62-9
- Deoxyshikonin
Catalog No.:BCN3006
CAS No.:43043-74-9
- Vinpocetine
Catalog No.:BCN2609
CAS No.:42971-09-5
- Cathepsin G Inhibitor I
Catalog No.:BCC3598
CAS No.:429676-93-7
- Dabigatran ethyl ester
Catalog No.:BCC1512
CAS No.:429658-95-7
- Nabumetone
Catalog No.:BCC4434
CAS No.:42924-53-8
- Z-Abu-OH
Catalog No.:BCC3201
CAS No.:42918-86-5
- Cladribine
Catalog No.:BCC1173
CAS No.:4291-63-8
- Zopiclone
Catalog No.:BCC9195
CAS No.:43200-80-2
- 6-(5-Chloropyridin-2-yl)-7-hydroxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-one
Catalog No.:BCC8753
CAS No.:43200-81-3
- Skp2 Inhibitor C1
Catalog No.:BCC6298
CAS No.:432001-69-9
- Fenbendazole
Catalog No.:BCC1236
CAS No.:43210-67-9
- Formoterol Hemifumarate
Catalog No.:BCC4349
CAS No.:43229-80-7
- 6-Hydroxykaempferol
Catalog No.:BCN3334
CAS No.:4324-55-4
- Boc-Tyr-OMe
Catalog No.:BCC3459
CAS No.:4326-36-7
- Toddaculine
Catalog No.:BCN3639
CAS No.:4335-12-0
- 3-O-Acetyloleanolic acid
Catalog No.:BCN5486
CAS No.:4339-72-4
- VU 0357121
Catalog No.:BCC4595
CAS No.:433967-28-3
- Ethisterone
Catalog No.:BCC4478
CAS No.:434-03-7
- Methenolone acetate
Catalog No.:BCC9028
CAS No.:434-05-9
[Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH].[Pubmed:12094708]
Hinyokika Kiyo. 2002 May;48(5):269-73.
One hundred and twenty-nine patients with benign prostatic hypertrophy (BPH) were registered and treated with Allylestrenol. Allylestrenol was administered at a dose of 50 mg/day given twice a day for 16 weeks. Out of 129 patients with a mean age of 67.8 years old, 92 cases completed the study and 48 cases with moderate symptoms were objectively evaluated with "Criteria for Treatment Efficacy in BPH" proposed by The Japanese Urological Association in 1997. Prostate volume was significantly decreased from 32.7 +/- 11.9 to 27.4 +/- 11.2 ml (mean +/- SD), and maximum flow rate was significantly increased from 8.4 +/- 3.4 to 10.8 +/- 5.0 ml/sec. Residual urine volume was significantly decreased from 62.4 +/- 57.4 to 37.0 +/- 38.7 ml. IPSS was significantly decreased from 15.3 +/- 4.9 to 9.9 +/- 4.0, and QOL index was significantly decreased from 4.4 +/- 0.8 to 2.7 +/- 1.2. The efficacy of Allylestrenol was shown by its effects on prostate volume (anatomy), maximum urinary flow rate (function), and symptom scores (symptom) at the end of 16 weeks of treatment. The rates of improvement for symptoms, QOL, function, and anatomy are 68.7% (N = 48), 79.2% (N = 48), 50.0% (N = 48), and 61.0% (N = 41), respectively. Overall efficacy (Good and Fair) was 70.9% (N = 48). During this study, 5 patients (3.9%) complained of loss of libido and 2 patients dropped out. In conclusion, Allylestrenol was demonstrated to be a quite effective and safe medical treatment for patients with symptomatic BPH based on the criteria for treatment efficacy in BPH.
Similarities and dissimilarities of newborn and adolescent rats in the binding capacity of thymic glucocorticoid receptors.[Pubmed:11311319]
Mech Ageing Dev. 2001 Mar;122(3):327-34.
The glucocorticoid receptor of the newborn thymus binds dexamethasone with the same specificity, as the adult ones. The best competitors of dexamethasone on the glucocorticoid receptor are dexamethasone itself and mifepristone (RU486). Estradiol can compete with dexamethasone on the glucocorticoid receptor. This is true in the case of newborn or adolescent thymus alike. Allylestrenol can slightly compete with dexamethasone on the glucocorticoid receptor in newborn, however this does not occur in adolescents. The other ligands - causing imprinting or imprinting like phenomenon earlier -- as tocopherol, menadione, retinoic acid, vitamin D(3) -- do not compete in vitro with dexamethasone on the thymic glucocorticoid receptor in newborn and adolescent animals. Possibilities of imprinting mechanism, considering the results are discussed.
Clinical significance of interruption of therapy with allylestrenol in patients with benign prostatic hypertrophy.[Pubmed:9781436]
Int J Urol. 1998 Sep;5(5):466-70.
BACKGROUND: A multicenter, clinical trial investigated the effects of an interruption of antiandrogen therapy on subjective and objective clinical parameters in patients with benign prostatic hypertrophy (BPH). METHODS: Patients were given antiandrogen therapy with Allylestrenol (50 mg/day) for 16 weeks. The medication was then withheld and the patients were carefully monitored for an additional 16 weeks. There were 34 BPH patients ranging in age from 55 to 82 years (mean, 66.1 years). The efficacy of Allylestrenol was evaluated by its effects on prostate volume, maximum urinary flow rate (MFR), and symptom scores at the end of 16 weeks of treatment and then again at 32 weeks (16 weeks after cessation of therapy). RESULTS: Allylestrenol was effective in the treatment of BPH, and was still effective 16 weeks after the cessation of medication. The prostate volume did not change after treatment cessation nor did the total symptom score, but the MFR reversed to the pretreatment level. Serum testosterone (1.95 ng/mL), dihydrotestosterone, and gonadotropin levels decreased on therapy, but were completely reversed by the end of this study. A prostate needle biopsy revealed that after 16 weeks without therapy, some glands showed regressive glandular changes, while some glands showed slight hyperplastic changes of the secretory epithelium. Eight per cent of patients complained of loss of libido during this study. CONCLUSIONS: Allylestrenol is an effective and safe medical treatment for patients with symptomatic BPH. Hormonal and histopathologic findings suggest that the prostate gland may regrow after discontinuation of medication.
